Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Inventory: 2013-2018

Historic Inventory for Theravance Biopharma (TBPH) over the last 5 years, with Sep 2018 value amounting to $17.9 million.

  • Theravance Biopharma's Inventory rose 17.47% to $17.9 million in Q3 2018 from the same period last year, while for Sep 2018 it was $17.9 million, marking a year-over-year increase of 17.47%. This contributed to the annual value of $16.8 million for FY2017, which is 37.73% up from last year.
  • Per Theravance Biopharma's latest filing, its Inventory stood at $17.9 million for Q3 2018, which was up 0.09% from $17.9 million recorded in Q2 2018.
  • Theravance Biopharma's 5-year Inventory high stood at $17.9 million for Q3 2018, and its period low was $9.4 million during Q1 2016.
  • Over the past 3 years, Theravance Biopharma's median Inventory value was $13.2 million (recorded in 2017), while the average stood at $14.0 million.
  • As far as peak fluctuations go, Theravance Biopharma's Inventory decreased by 23.76% in 2016, and later skyrocketed by 47.67% in 2018.
  • Over the past 5 years, Theravance Biopharma's Inventory (Quarterly) stood at $12.5 million in 2014, then declined by 20.25% to $10.0 million in 2015, then climbed by 22.14% to $12.2 million in 2016, then spiked by 37.73% to $16.8 million in 2017, then grew by 17.47% to $17.9 million in 2018.
  • Its last three reported values are $17.9 million in Q3 2018, $17.9 million for Q2 2018, and $17.2 million during Q1 2018.